Similar articles for PMID: 22380826

Year	Number of Results
2001	1
2008	1
2009	6
2010	12
2011	14
2012	13
2013	9
2014	12
2015	19
2016	13
2017	8
2018	2
2019	6
2020	2
2021	3
2022	9
2023	3
2024	0

1

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.

Garçon N, Vaughn DW, Didierlaurent AM. Garçon N, et al. Expert Rev Vaccines. 2012 Mar;11(3):349-66. doi: 10.1586/erv.11.192. Expert Rev Vaccines. 2012. PMID: 22380826 Review.

2

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.

van der Most RG, Clément F, Willekens J, Dewé W, Walravens K, Vaughn DW, Leroux-Roels G. van der Most RG, et al. Clin Vaccine Immunol. 2017 Jun 5;24(6):e00553-16. doi: 10.1128/CVI.00553-16. Print 2017 Jun. Clin Vaccine Immunol. 2017. PMID: 28446441 Free PMC article. Clinical Trial.

3

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garçon N, Van Mechelen M. Morel S, et al. Vaccine. 2011 Mar 16;29(13):2461-73. doi: 10.1016/j.vaccine.2011.01.011. Epub 2011 Jan 20. Vaccine. 2011. PMID: 21256188

4

Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.

Langley JM, Reich D, Aggarwal N, Connor D, Lebel MH, Gupta A, Garfield H, Li P, Madan A, Vaughn DW. Langley JM, et al. Pediatr Infect Dis J. 2012 Aug;31(8):848-58. doi: 10.1097/INF.0b013e31825e6cd6. Pediatr Infect Dis J. 2012. PMID: 22801094 Clinical Trial.

5

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.

Madan A, Segall N, Ferguson M, Frenette L, Kroll R, Friel D, Soni J, Li P, Innis BL, Schuind A. Madan A, et al. J Infect Dis. 2016 Dec 1;214(11):1717-1727. doi: 10.1093/infdis/jiw414. Epub 2016 Sep 7. J Infect Dis. 2016. PMID: 27609809 Free PMC article. Clinical Trial.

6

A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine.

Langley JM, Frenette L, Chu L, McNeil S, Halperin S, Li P, Vaughn D. Langley JM, et al. BMC Infect Dis. 2012 Oct 30;12:279. doi: 10.1186/1471-2334-12-279. BMC Infect Dis. 2012. PMID: 23110320 Free PMC article. Clinical Trial.

7

Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.

Waddington C, Andrews N, Hoschler K, Walker W, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston P, Allen R, Okike I, Ladhani S, Sheasby E, Waight P, Collinson A, Heath P, Finn A, Faust S, Snape M, Miller E, Pollard A. Waddington C, et al. Health Technol Assess. 2010 Oct;14(46):1-130. doi: 10.3310/hta14460-01. Health Technol Assess. 2010. PMID: 20923610 Free article. Clinical Trial.

8

An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.

Poder A, Simurka P, Li P, Roy-Ghanta S, Vaughn D. Poder A, et al. Vaccine. 2014 Feb 19;32(9):1121-9. doi: 10.1016/j.vaccine.2013.11.031. Epub 2013 Nov 16. Vaccine. 2014. PMID: 24252703 Free article. Clinical Trial.

9

Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age.

Izurieta P, Uy-Aragon MJ, Dramé M, Vaughn DW. Izurieta P, et al. Pediatr Infect Dis J. 2016 Feb;35(2):e35-47. doi: 10.1097/INF.0000000000000968. Pediatr Infect Dis J. 2016. PMID: 26551446 Clinical Trial.

10

Comparative pharmacokinetic and biodistribution study of two distinct squalene-containing oil-in-water emulsion adjuvants in H5N1 influenza vaccines.

Tegenge MA, Von Tungeln LS, Anderson SA, Mitkus RJ, Vanlandingham MM, Forshee RA, Beland FA. Tegenge MA, et al. Regul Toxicol Pharmacol. 2019 Nov;108:104436. doi: 10.1016/j.yrtph.2019.104436. Epub 2019 Aug 2. Regul Toxicol Pharmacol. 2019. PMID: 31381939

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

117 results

Results by year